This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Endocrine/metabolic disease

Obesity

Lactadherin (MFGE8; HMFG); integrin aVb5; integrin aVb3 (CD51/CD61)

Mouse studies suggest inhibiting MFGE8 could help reduce fat uptake and treat obesity. In Mfge8 knockout mice fed a high-fat diet, insulin sensitivity increased and weight gain and total body fat decreased compared with what was seen in wild-type mice fed a high-fat diet. In mice treated with recombinant Mfge8, injection of antibodies blocking the Mfge8 receptors integrin aV or integrins b5 or b3 decreased serum, hepatic and enterocyte triglyceride contents compared with control antibody. Next steps include developing antibodies against human MFGE8 and investigating local and systemic integrin aVb5 inhibition in mouse models of obesity (see Curb your fatty acids, page 1).

SciBX 7(6); doi:10.1038/scibx.2014.175
Published online Feb. 13, 2014

Provisional patent application filed; available for licensing

Khalifeh-Soltani, A. et al. Nat. Med.; published online Jan. 19, 2014;
doi:10.1038/nm.3450
Contact: Kamran Atabai, University of California, San Francisco, Calif.
e-mail:
kamran.atabai@ucsf.edu